Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
30.26
+0.20 (0.67%)
At close: Jul 31, 2025, 4:00 PM
30.26
0.00 (0.00%)
After-hours: Jul 31, 2025, 4:10 PM EDT
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $40.83, which forecasts a 34.93% increase in the stock price over the next year. The lowest target is $34 and the highest is $54.
Price Target: $40.83 (+34.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Jefferies | Jefferies | Strong Buy Maintains $45 → $54 | Strong Buy | Maintains | $45 → $54 | +78.45% | Jul 29, 2025 |
Wells Fargo | Wells Fargo | Buy Maintains $30 → $42 | Buy | Maintains | $30 → $42 | +38.80% | Jul 9, 2025 |
Jefferies | Jefferies | Strong Buy Maintains $40 → $45 | Strong Buy | Maintains | $40 → $45 | +48.71% | Apr 29, 2025 |
Wedbush | Wedbush | Buy Reiterates $34 | Buy | Reiterates | $34 | +12.36% | Apr 16, 2025 |
Citigroup | Citigroup | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +32.19% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
580.73M
from 423.24M
Increased by 37.21%
Revenue Next Year
616.15M
from 580.73M
Increased by 6.10%
EPS This Year
0.74
from -0.60
EPS Next Year
0.43
from 0.74
Decreased by -41.52%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 655.3M | 742.4M | 871.1M | ||
Avg | 616.2M | 700.6M | 816.6M | ||
Low | 585.1M | 646.6M | 759.5M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 54.8% | 20.5% | 24.3% | ||
Avg | 45.6% | 13.7% | 16.6% | ||
Low | 38.2% | 4.9% | 8.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 1.05 | 1.60 | 2.21 | ||
Avg | 0.43 | 1.26 | 1.50 | ||
Low | -0.23 | 0.98 | 0.82 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | 269.8% | 74.5% | ||
Avg | - | 192.2% | 18.7% | ||
Low | - | 126.6% | -34.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.